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Background: Proteinuria and hematuria are both important health issues; however, the nature of the association
between these findings and acute kidney injury (AKI) or mortality remains unresolved in critically ill patients.
Methods: Proteinuria and hematuria were measured by a dipstick test and scored using a scale ranging from a
negative result to 3+ in 1883 patients admitted to the intensive care unit. AKI was defined according to the Kidney
Disease: Improving Global Outcomes (KDIGO) guidelines. The odds ratios (ORs) for AKI and 3-year mortality were
calculated after adjustment for multiple covariates according to the degree of proteinuria or hematuria. For
evaluating the synergistic effect on mortality among proteinuria, hematuria, and AKI, the relative excess risk due to
interaction (RERI) was used.
Results: Proteinuria and hematuria increased the ORs for AKI: the ORs of proteinuria were 1.66 (+/−), 1.86 (1+), 2.18
(2+), and 4.74 (3+) compared with non-proteinuria; the ORs of hematuria were 1.31 (+/−), 1.58 (1+), 2.63 (2+), and
2.52 (3+) compared with non-hematuria. The correlations between the mortality risk and proteinuria or hematuria
were all significant and graded (Ptrend < 0.001). There was a relative excess risk of mortality when both AKI and
proteinuria or hematuria were considered together: the synergy indexes were 1.30 and 1.23 for proteinuria and
hematuria, respectively.
Conclusions: Proteinuria and hematuria are associated with the risks of AKI and mortality in critically ill patients.
Additionally, these findings had a synergistic effect with AKI on mortality.
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Acute kidney injury (AKI) is a major focus of study in
nephrology because AKI is related to an increase in
morbidity and mortality [1,2]. Although therapy for AKI
has improved in recent years, AKI is still highly preva-
lent, especially in critically ill patients in the intensive
care unit (ICU) [3]. AKI in the ICU has extremely high
mortality rates, reaching 80% [4]; this rate has remained
relatively unchanged despite improved therapies [5]. For
these reasons, the detection and management of factors* Correspondence: imsejoong@hanmail.net
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unless otherwise stated.related to AKI are important concerns for clinicians in
managing AKI patients.
Urinary abnormalities include proteinuria, hematuria,
oliguria, frequency, and polyuria. These features can be
encountered in various clinical settings; oliguria, one of
the possible findings, comprises 50% of AKI cases [6]
and is included in the criteria for defining AKI [7].
However, other urinary features such as proteinuria and
hematuria have not been thoroughly considered in con-
nection with AKI. Proteinuria and hematuria can be
easily screened by a dipstick test. These are increasingly
recognized as important markers of disease that carry
risks for end-stage renal disease [8]. Previous studies
have described the association between AKI and pro-
teinuria or hematuria in certain clinical settings, such as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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globulin A nephropathy [13], and warfarin-induced ne-
phropathy [14]. However, these studies have not considered
proteinuria and hematuria together or the ICU patients
who have a high risk of AKI and mortality. The combined
study of proteinuria, hematuria, and AKI may be necessary
to improve the predictability of outcomes, but there are
also no studies that address this issue.
Herein, we aim to verify whether proteinuria or
hematuria increase the risks of AKI or mortality in a
large cohort of ICU patients. Furthermore, we examine
the synergistic effect of proteinuria, hematuria, and AKI
for predicting mortality.
Methods
Participants and data collection
The study protocol complies with the Declaration of
Helsinki and had ethics approval from the institutional
review board at the Seoul National University Bundang
Hospital (no. B-1304/200-108). A total of 2823 patients
were consecutively recruited from June 2004 through
June 2010, who were admitted to the ICU at the Seoul
National University Bundang Hospital, Gyeonggi-do,
Korea. The patients were followed up until June 30, 2010.
We excluded patients younger than 18 years old (n = 49)
and patients previously diagnosed with end stage renal
disease on dialysis (n = 94). The patients for whom data
were missing, including serum creatinine, urine output, or
dipstick test results, were also excluded (n = 250). Lastly,
the patients with a daily urine output of less than 50 mL/
day or anuria were excluded (n = 23). If the patients were
admitted more than once to the ICU, only the first admis-
sion was counted as the single case. Consequently, 1883
patients were reviewed retrospectively using electronic
medical records. The need for informed consent was
waived because of non-interventional study design based
on routinely collected data.
Clinical parameters, such as age, sex, weight, systolic/
diastolic blood pressure, primary diagnosis, underlying
chronic kidney disease, diabetes mellitus, history of ma-
lignancy, the need for mechanical ventilation, and the
use of vasoactive drugs, were recorded. The primary
diagnoses included cardiovascular disease, sepsis, surgi-
cal admission, and others. The Acute Physiology and
Chronic Health Evaluation (APACHE) ІІ score was used
to assess illness severity [15]. Changes in serum creatin-
ine and urine output after ICU admission were mea-
sured, and the urine output data were recorded hourly.
A dipstick test was used to score the degrees of protein-
uria and hematuria using a scale ranging from a negative
result to +3 using an automated urine chemistry
analyzer (CLINITEK Novus Analyzer, Siemens, Erlangen,
Germany). There were no missing data for any of the
variables.The risk of AKI was determined from admission to
15 days in the ICU. For the definition and staging of AKI,
both the serum creatinine and the urine output criteria
were used according to the guideline proposed by the
Kidney Disease: Improving Global Outcomes (KDIGO)
[7]. The 3-year mortality from all causes was also con-
sidered to be the primary outcome. The mortality data
were obtained from the national database of Statistics
Korea.
Statistical analysis
All of the analyses and calculations were performed
using STATA (STATA version 12.0, StataCorp LP, College
Station, Texas, USA). The data are presented as means ±
standard deviation (SD) for continuous variables and as
proportions for categorical variables. Comparisons were
measured using the chi-squared test for categorical vari-
ables (e.g., AKI stages) among the proteinuria and
hematuria groups. Mortality curves were drawn using
the Kaplan-Meier method. A logistic regression analysis
was used to examine the risk of AKI or 3-year mortality
according to the presence of proteinuria or hematuria.
The effects of the logistic regression model are shown
as odds ratios (ORs) and 95% confidence intervals (CIs).
For this analysis, ORs were adjusted for multiple covari-
ates, such as age, sex, body weight, primary diagnosis,
underlying chronic kidney disease, diabetes mellitus,
history of malignancy, the need for mechanical ventila-
tion, the use of vasoactive drugs, and APACHE ІІ score.
To evaluate the synergistic effect on mortality of pro-
teinuria, hematuria, and AKI, the relative excess risk
due to interaction (RERI) was used [16]. The RERI is an
approach to estimate the additive interaction of two var-
iables on an odds ratio scale. From the RERI method,
we present three scales: RERI (part of the total effect
that is due to interaction), AP (proportion of the com-
bined effect that is due to interaction), and synergy
index (ratio between combined effect and individual ef-
fects). Positive results for RERI and AP and a value
greater than 1 for the synergy index means a positive
interaction or more than additivity between variables.
Additionally, the discrimination of predicting mortality
between AKI and proteinuria or hematuria was assessed
by calculating the receiver operating characteristic
(ROC) curve and the area under the curve (AUC). The
comparison of ROC curves was tested using a method
described by DeLong ER et al. [17]. A P value of less
than 0.05 was considered significant.
Results
Baseline characteristics
Among a total of 1883 subjects, the mean age was
68 years old (Table 1). All of the subjects were of Asian
descent. Most of the patients were admitted to the ICU
Table 1 Baseline characteristics and laboratory findings
of the patients at the time of admission to the intensive
care unit
Total (n = 1883)
Age (years) 67.8 ± 15.88
Male sex (%) 59.9






Underlying chronic kidney disease (%) 8.7
Diabetes mellitus (%) 12.2
History of malignancy (%) 15.3
Need for mechanical ventilation (%) 69.6
Use of vasoactive drugs (%) 51.4
Systolic blood pressure (mmHg) 130.2 ± 31.52
Diastolic blood pressure (mmHg) 73.0 ± 20.82













APACHE ІІ score 18.4 ± 8.04
Length of stay in hospital (days)* 22 (11 to 45)
*Data are expressed as the median (interquartile range (IQR)) when the
distribution of data was skewed.
APACHE, Acute Physiology and Chronic Health Evaluation.
Han et al. BMC Nephrology 2014, 15:93 Page 3 of 8
http://www.biomedcentral.com/1471-2369/15/93because of medical problems (n = 1848) rather than sur-
gical problems (n = 35). More specifically, 580 patients
(30.8%) were admitted to the ICU because of cardiovas-
cular disease. Sepsis was the cause of admission for 86
patients (4.6%). The proportion of subjects with trace
levels or higher for proteinuria was 67.4% and for
hematuria was 77.5%. The mean APACHE ІІ score was
18.4. The median length of stay in the hospital was
22 days (IQR, 11 to 45 days). The study subjects were
followed for a median duration of 480 days (IQR, 37 to
1797 days).Risk of acute kidney injury according to proteinuria and
hematuria
A total of 78.7% of the subjects had AKI within 15 days
after admission to the ICU. 74.7% of total AKI cases
were determined at the time of ICU admission, and
other cases (25.3%) developed from 2 days to 15 days of
admission. Each AKI case was diagnosed by serum cre-
atinine criterion alone (68.1%), urine output criterion
alone (2.8%), or both (29.1%). The proportion in each
AKI stage was as follows: stage 1, 47.1%; stage 2, 29.7%;
and stage 3, 23.2%. Among stage 3 of AKI, 132 subjects
(38.4%) received renal replacement therapy. Table 2 shows
the risk of AKI according to the presence of proteinuria
and hematuria. The risk of AKI gradually increased from
the trace level of proteinuria. For hematuria, the risk of
AKI increased from the first positive level. The correla-
tions of AKI risk with proteinuria or hematuria remained
consistent, irrespective of adjustments made to multiple
variables. When patients with both proteinuria (trace or
more) and hematuria (1+ or more) (n = 966) were com-
pared with patients without both markers (n = 363), the
adjusted HR for AKI was 2.86 (2.102–3.901) (P < 0.001).
After excluding the AKI cases with onset at day 0, protein-
uria and hematuria groups had greater AKI risks (with on-
set on day 1 to 15) compared with the groups without
proteinuria or hematuria as following adjusted HRs:
proteinuria [+/−, 1.69 (1.088–2.624) (P = 0.020); 1+,
1.49 (1.003–2.212) (P = 0.047); 2+, 1.58 (0.991–2.514)
(P = 0.053); 3+, 2.53 (0.987–6.463) (P = 0.052); Ptrend =
0.037]; hematuria [+/−, 1.02 (0.621–1.660) (P = 0.951);
1+, 1.47 (0.901–2.409) (P = 0.122); 2+, 2.10 (1.315–
3.356) (P = 0.002); 3+, 1.65 (1.076–2.528) (P = 0.022);
Ptrend = 0.010].
We further evaluated whether the correlations with
proteinuria or hematuria were significant when only one
of two criteria (serum creatinine criterion and urine out-
put criterion) was used for identifying AKI. Although
the AKI cases were divided by two criteria, proteinuria
had greater adjusted ORs for AKI compared with the
group without proteinuria as follows; by serum creatinine
criterion [+/−, 1.49 (1.054–2.115) (P = 0.024); 1+, 1.67
(1.236–2.262) (P = 0.001); 2+, 2.01 (1.417–2.860) (P <
0.001); 3+, 2.90 (1.534–5.479) (P = 0.001); Ptrend < 0.001];
by urine output criterion [+/−, 1.49 (1.028–2.145) (P =
0.035); 1+, 1.96 (1.437–2.667) (P < 0.001); 2+, 2.07 (1.481–
2.882) (P < 0.001); 3+, 5.26 (3.310–8.355) (P < 0.001);
Ptrend < 0.001]. When the patients were compared
among the hematuria and non-hematuria groups, the
associations with AKI were also significant according to
each criterion; by serum creatinine criterion [+/−, 1.32
(0.914–1.918) (P = 0.137); 1+, 1.63 (1.105–2.403) (P =
0.014); 2+, 2.62 (1.808–3.784) (P < 0.001); 3+, 2.29
(1.663–3.150) (P < 0.001); Ptrend < 0.001]; by urine out-
put criterion [+/−, 0.97 (0.639–1.478) (P = 0.895); 1+,
Table 2 Odds ratios for acute kidney injury according to proteinuria and hematuria
Univariate Multivariate*
OR (95% CI) P OR (95% CI) P
Proteinuria < 0.001† < 0.001†
- (n = 614) 1 (Reference) 1 (Reference)
+/− (n = 290) 1.99 (1.426–2.777) < 0.001 1.66 (1.160–2.385) 0.006
1+ (n = 503) 2.59 (1.938–3.468) < 0.001 1.86 (1.362–2.551) < 0.001
2+ (n = 363) 3.04 (2.166–4.278) < 0.001 2.18 (1.511–3.135) < 0.001
3+ (n = 113) 6.53 (3.121–13.663) < 0.001 4.74 (2.199–10.221) < 0.001
Hematuria < 0.001† < 0.001†
- (n = 423) 1 (Reference) 1 (Reference)
+/− (n = 243) 1.25 (0.884–1.761) 0.208 1.31 (0.895–1.906) 0.167
1+ (n = 236) 1.63 (1.132–2.341) 0.009 1.58 (1.063–2.349) 0.024
2+ (n = 363) 2.83 (1.989–4.029) <0.001 2.63 (1.796–3.853) <0.001
3+ (n = 618) 3.15 (2.315–4.273) <0.001 2.52 (1.808–3.523) <0.001
*Adjusted for age, sex, body weight, primary diagnosis, underlying chronic kidney disease, diabetes mellitus, history of malignancy, the need for mechanical
ventilation, the use of vasoactive drugs, and APACHE ІІ score.
†P for trend.
OR, odds ratio; CI, confidence interval.
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(P = 0.372); 3+, 1.82 (1.333–2.479) (P < 0.001)].
The AKI stages in each degree of proteinuria or
hematuria are shown in Figure 1. When compared with
the group without proteinuria or hematuria, the
groups with proteinuria or hematuria demonstrated
significant differences in AKI stages; the presence of
proteinuria or hematuria led to a tendency toward
higher AKI stages than the absence of proteinuria or
hematuria (all Ps < 0.05). The worst case of AKI (stage
ІІІ) developed more strongly in the groups with pro-
teinuria or hematuria with the following adjusted ORs
(95% CI); proteinuria groups vs. non-proteinuria group
[+/−, 2.19 (1.423–3.364) (P < 0.001); 1+, 2.75 (1.902–
3.970) (P < 0.001); 2+, 2.44 (1.637–3.629) (P < 0.001); 3+,
6.48 (3.900–10.754) (P < 0.001)]; hematuria groups vs.
non-hematuria group [+/−, 1.42 (0.867–2.338) (P = 0.162);Figure 1 Proportions of acute kidney injury stages in each group: pro1+, 1.54 (0.946–2.516) (P = 0.082); 2+, 1.78 (1.166–2.727)
(P = 0.007); 3+, 2.59 (1.784–3.759) (P < 0.001)].
Impact of proteinuria and hematuria on mortality
Throughout the follow-up period, 1270 (67.4%) of all
ICU patients died, and the mortality rate was 69.9 deaths
per 100000 patient-days. As shown in Table 3, the pres-
ence of proteinuria or hematuria worsened the mortality,
irrespective of the effects of covariates. Although the AKI
was further adjusted, the overall correlations between
mortality and proteinuria or hematuria were significant
as follows: ORs (95% CI) in proteinuria groups vs. non-
proteinuria group [+/−, 1.48 (1.054–2.066) (P = 0.023);
1+, 1.71 (1.280–2.273) (P < 0.001); 2+, 1.85 (1.347–
2.540) (P < 0.001); 3+, 1.66 (1.009–2.733) (P = 0.046)];
in the hematuria groups vs. non-hematuria group [+/−,
1.13 (0.773–1.652) (P = 0.528); 1+, 1.27 (0.866–1.847)teinuria (A) and hematuria (B).
Table 3 Odds ratios for 3-year mortality according to proteinuria and hematuria
Univariate Multivariate*
OR (95% CI) P OR (95% CI) P
Proteinuria < 0.001† < 0.001†
- (n = 614) 1 (Reference) 1 (Reference)
+/− (n = 290) 1.78 (1.340–2.364) < 0.001 1.59 (1.140–2.213) 0.006
1+ (n = 503) 2.23 (1.750–2.845) < 0.001 1.86 (1.403–2.472) < 0.001
2+ (n = 363) 2.49 (1.898–3.268) < 0.001 2.09 (1.524–2.854) < 0.001
3+ (n = 113) 2.14 (1.407–3.239) < 0.001 2.04 (1.239–3.343) 0.005
Hematuria < 0.001† < 0.001†
- (n = 423) 1 (Reference) 1 (Reference)
+/− (n = 243) 1.08 (0.785–1.477) 0.646 1.17 (0.808–1.703) 0.401
1+ (n = 236) 1.32 (0.955–1.814) 0.094 1.34 (0.921–1.944) 0126
2+ (n = 363) 1.67 (1.257–2.227) < 0.001 1.55 (1.104–2.163) 0.011
3+ (n = 618) 1.76 (1.370–2.268) < 0.001 1.65 (1.225–2.232) 0.001
*Adjusted for age, sex, body weight, primary diagnosis, underlying chronic kidney disease, diabetes mellitus, history of malignancy, the need for mechanical
ventilation, the use of vasoactive drugs, and APACHE ІІ score.
†P for trend.
OR, odds ratio; CI, confidence interval.
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(1.078–1.988) (P = 0.015)]. The trends in the correla-
tions of mortality with proteinuria (Ptrend < 0.001) and
hematuria (Ptrend = 0.010) were also significant after
further adjustment of AKI. When patients with both
proteinuria (trace or more) and hematuria (1+ or more)
were compared with patients without both markers,
the adjusted HR for mortality was 2.07 (1.545–2.772)
(P < 0.001).
There was a trend of interaction between AKI and
proteinuria for mortality (P for interaction = 0.089) or
between AKI and hematuria (P for interaction = 0.077).
We evaluated whether there was a synergistic effect for
mortality between AKI and proteinuria or hematuria
using the RERI method. Because the outcomes increased
above the level of non-proteinuria or trace levels of
hematuria, the subjects were divided into two groups
as follows: non-proteinuria vs. trace or more for pro-
teinuria; non-hematuria and trace vs. 1+ or more for
hematuria. Tables 4 and 5 show the RERI results be-




OR (95% CI) N
o
No AKI 52/152 1 (Reference) 8
AKI 231/179 3.77 (2.604–5.464)* 7
OR for AKI within strata
of proteinuria status
3.77 (2.604–5.464)*
Measure of interaction on additive scale: RERI (95% CI) = 1.26 (−0.153–2.556); AP (95
*P < 0.001.
OR, odds ratio; CI, confidence interval; AKI, acute kidney injury; RERI, relative excessFor both proteinuria and hematuria, the RERI and AP
scales were positive, and the synergy indexes were
greater than 1; this means there was a relative excess
risk of mortality when both AKI and proteinuria or
hematuria were considered together. The presence of
proteinuria or hematuria further separated the AKI-
considered survival curves of ICU patients (Figure 2).
There was no interaction for AKI or mortality between
proteinuria and hematuria (P = 0.962).
ROC curves for the prediction of acute kidney injury and
mortality
We evaluated the ROC curves in proteinuria and hematuria
for the prediction of AKI with following AUCs; proteinuria,
0.639 (0.609–0.669); hematuria, 0.630 (0.599–0.661);
and proteinuria + hematuria, 0.648 (0.618–0.678). All of
AUCs were significantly larger than the reference line
(all Ps < 0.001). We further evaluated whether the pre-
dictability of mortality by AKI is improved by the add-
itional consideration of proteinuria and hematuria using




OR (95% CI) OR for proteinuria within
strata of AKI status
9/109 2.39 (1.566–3.637)* 2.39 (1.566–3.637)*
36/335 6.42 (4.569–9.026)* 1.70 (1.347–2.151)*
2.69 (1.977–3.663)*
% CI) = 0.20 (−0.230–0.356); SI (95% CI) = 1.30 (0.974–1.750).
risk due to interaction; AP, attributable proportion; SI, synergy index.




OR (95% CI) N with/without
outcome
OR (95% CI) OR for proteinuria within
strata of AKI status
No AKI 65/144 1 (Reference) 76/117 1.44 (0.954–2.171) 1.44 (0.954–2.171)
AKI 278/179 3.44 ( 2.430–4.872)† 689/335 4.56 (3.306–6.279)† 1.32 (1.054–1.665)*
OR for AKI within strata
of hematuria status
3.44 ( 2.430–4.872)† 3.17 (2.306–4.347)†
Measure of interaction on additive scale: RERI (95% CI) = 0.68 (−0.543–1.665); AP (95% CI) = 0.15 (−0.118–0.347); SI (95% CI) = 1.23 (0.864–1.853).
*P < 0.05; †P < 0.001.
OR, odds ratio; CI, confidence interval; AKI, acute kidney injury; RERI, relative excess risk due to interaction; AP, attributable proportion; SI, synergy index.
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model. The AUCs (95% CI) for mortality in each pro-
teinuria and hematuria model were 0.597 (0.572–0.623)
and 0.565 (0.539–0.591), respectively. The AUCs for
mortality in the combined models of AKI and urine
findings were significantly higher than the AUC calcu-
lated using AKI only: AKI + proteinuria, 0.646 (0.620–
0.671) (P < 0.001); AKI + hematuria, 0.627 (0.602–0.653)
(P = 0.011); and AKI + proteinuria + hematuria, 0.647
(0.621–0.673) (P < 0.001).
Discussion
The mortality among ICU patients is extremely high,
and AKI worsens this outcome. For predicting and man-
aging the mortality attributable to AKI, several markers
have been considered. Among them, proteinuria and
hematuria are easily examined by a simple dipstick test,
but these findings may be paradoxically overlooked des-
pite the inexpensive and easily accessible examination
and the intrinsic features of the test. The present study
first examines the correlation between AKI and protein-
uria or hematuria in ICU patients. Both proteinuria and
hematuria predicted the prevalence of AKI. This was
consistent regardless of whether AKI was defined by the
onset or the criteria. The severity of AKI generally de-
scribed by stages was higher in the high-degree of protein-
uria or hematuria group than in the low-degree group.
Both proteinuria and hematuria had a significant associ-
ation with mortality and additionally had a synergisticFigure 2 Kaplan-Meier survival curves according to the presence of Aeffect with AKI. Lastly, the predictability of mortality in
the AKI model was improved by considering proteinuria,
hematuria, or both.
Proteinuria has been regarded as being important,
especially in the field of chronic kidney disease [18].
This is mainly because proteinuria has an impact on
mortality, with an effect on mortality similar to smok-
ing [19]. However, the relationship between protein-
uria and AKI is not fully established, especially in ICU
patients. Previous data on a large cohort of outpatients
showed an additive role of proteinuria in predicting
the risk of AKI admission [9], although the baseline
characteristics were relatively robust (AKI prevalence
< 1%). Other cohorts of patients with cardiac surgery
and burns, conditions that carry a high risk of AKI,
also supported the association between proteinuria and
AKI risk [10-12], although those studies did not cover
a heterogeneous population of critically ill patients.
The present study, which included a large cohort of critic-
ally ill patients, builds on the previous study results with
respect to the significant correlation between proteinuria
and the risk of AKI. Furthermore, it is intriguing that pro-
teinuria and AKI had a synergistic effect on mortality. This
means that the risk of mortality is greater than the simple
additive risk when AKI and proteinuria are considered
together.
Hematuria is an important pathologic finding and thus
is included in the criteria for chronic kidney disease [7].
However, its presence is not usually mentioned in largeKI and proteinuria (A) or hematuria (B).
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most studies in the field of AKI do not focus on the
role of hematuria. A few studies described hematuria-
associated AKI in certain clinical settings such as
immunoglobulin A nephropathy or warfarin-induced
nephropathy [13,14], but it is difficult to apply these
data directly to subjects with a high risk of AKI. For
the first time, the present study demonstrates the asso-
ciations of hematuria with both AKI and mortality in
ICU patients. The effect size of hematuria seemed to
be small compared with that of proteinuria, but the effects
of hematuria (1+ or more) on AKI and mortality were in-
dependent of proteinuria with the following adjusted ORs
in the hematuria group compared with the non-hematuria
group: AKI, 1.88 (1.476–2.386) (P < 0.001); mortality, 1.27
(1.031–1.555) (P = 0.024). Furthermore, the predictability
of mortality in the AKI model was improved by the
addition of hematuria. Based on the present results,
further clinical and experimental studies are needed to
delineate the role of hematuria in AKI.
Proteinuria and hematuria may simply be markers of
underlying kidney disease or other organ status [18,20].
Precisely, urinary abnormalities are shown in more
than half of patients with acute tubular necrosis, which
is the most common cause of AKI in the ICU [21-23].
Accordingly, these findings may be associated with AKI
or mortality via acute tubular necrosis or other baseline
conditions. However, in the present study, the correla-
tions of proteinuria or hematuria with outcomes were
significant despite adjusting several baseline conditions.
Furthermore, both proteinuria and hematuria had an
association with the AKI cases with late onset. Investiga-
tions on the independent role of proteinuria or hematuria
in kidney damage and other types of organ damage are
ongoing. It is known that proteinuria induces signals for
tubulointerstitial inflammation and activates fibrogenic
pathways as a postulated mechanism of kidney damage
[24]. Proteinuria is also associated with endothelial dys-
function, which covers cardiovascular mortality [25].
Furthermore, other mechanisms affecting the overall
outcome of proteinuria may include an increased risk
of infection, thrombotic disease, or malnutrition [26],
although thorough investigations have not been con-
ducted. The subjects with hematuria are at risk of kid-
ney damage because hemoglobin, heme, iron, or other
molecules released from red blood cells are toxic to
the kidney tubular cells and thus induce inflammatory
cascades [27,28]. It is intriguing that the cessation of
hematuria is related to the recovery of kidney function
[13], although this is known only in immunoglobulin A
nephropathy, and there are no agents for this.
It is intriguing that hematuria was independently as-
sociated with high mortality risk in the ICU patients.
There are no observational studies or commentaries onthe direct correlation between hematuria and mortality.
However, it is known that hematuria increases the risk
of AKI or end-stage renal disease development [22,29].
Based on the evidence, we could propose only the follow-
ing mechanism: hematuria is a marker of kidney injury
and thus has a relationship with mortality via progressed
(or severe) kidney damage.
Although our results are informative, this study has
some limitations. First, the ICU design of the study
limits the applicability of our conclusions to other set-
tings, despite the abundance and detail of the dataset.
Furthermore, like all observational studies, the present
study does not prove causality. Second, the measure-
ment of proteinuria and hematuria by the dipstick test
only is a limitation because of the relatively low precision
and thus misclassification bias. However, such a bias
would have supported the null hypothesis, so the true cor-
relations are most likely stronger than the present study
results. Furthermore, the dipstick test is an inexpensive
and more accessible examination compared with a quanti-
tative urine test, which has implications in clinical prac-
tice. Third, we did not separate preexisting proteinuria
and hematuria from newly discovered cases after admis-
sion because all the admissions to the ICU were not
scheduled. This issue is the same when most patients who
are admitted to the ICU do not have the baseline serum
creatinine required for defining AKI in principle. However,
this condition may better fit the real clinical practice. Fur-
ther studies addressing these limitations will be necessary
in the future.Conclusions
Proteinuria and hematuria are both important pathologic
findings, but before the present study, we did not know
the relationship between these conditions and AKI or
mortality in critically ill patients. The present study cannot
determine whether reducing the amount of proteinuria or
hematuria decreases the risk of AKI or mortality in the
ICU subset. Furthermore, although the dipstick test has
the advantage of being inexpensive, the cost-effectiveness
of the dipstick test is not assured from the study results.
However, the present study will form the basis of later
studies to address these issues.Competing interest
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